A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region

Trial Profile

A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs TDENV LAV (Primary) ; TDENV PIV (Primary)
  • Indications Dengue
  • Focus Adverse reactions
  • Most Recent Events

    • 02 May 2017 Status changed from recruiting to completed.
    • 31 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
    • 28 May 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top